Nobody actually wants a comparison between Thailand and some abstract global average. What people want to know is whether Thailand beats the country they live in.

So here it is, including the parts that don’t flatter us.

The cost gap, in actual numbers

Published figures put the Thai market roughly 50% under United States pricing. For a comparable knee procedure that’s about $7,000 on the US side against something materially cheaper here.

Market	Comparable knee procedure	What drives the difference
United States	~$7,000 average, $4,000–$15,000+ range	Physician fees, facility overhead, malpractice insurance
Western Europe	€5,000–€12,000	Varies sharply by country; public systems rarely cover it
Australia	AUD 8,000–20,000	Limited provider supply pushes prices up
Thailand	Roughly 40–60% below US pricing	Lower labour and facility costs, more provider competition

Then add the trip, and the gap shrinks. Flights, a room, and time off work are real costs. We’ve broken that down properly in our 2026 price guide.

For a single procedure the saving can be modest once travel is counted. For multi-session protocols, or where the treatment simply isn’t available at home, the arithmetic changes completely.

Regulation, which cuts both ways

Comparison articles tend to get this wrong in one direction or the other. We won’t.

In the United States, the FDA treats most stem cell products as biologics. A therapy has to clear clinical trials and gain approval before it can be marketed for a specific condition. The result is a smaller menu of legally available treatments, sitting on a much stronger evidence base.

In Thailand, regenerative medicine operates inside a framework that permits physician-supervised treatment with autologous cells under professional standards, while allogeneic and cultured products face heavier oversight. Practically speaking, Thai clinics can offer protocols for conditions where US providers legally cannot. That’s exactly why some people travel.

Read that both ways, because it is genuinely double-edged.

• What you gain: access to protocols that exist in research and clinical practice but aren’t approved for your indication at home — often for conditions where nothing else has worked.
• What you take on: less of a safety net. In the US, FDA approval is a guarantee you don’t have to personally verify. In Thailand, verifying the clinic is your job. That’s the trade, and there’s no version of this where you get both.

We think patients should make that trade knowingly, which is why we publish the questions to ask any clinic — us included.

Wait times and access

In the US and much of Europe, access to regenerative treatment runs through two doors: an approved therapy, or a clinical trial. Trials have narrow enrolment criteria that exclude most applicants, and waiting lists measured in months or years.

Here, access is quick once you’re assessed. Most of our international patients go from first contact to treatment in four to eight weeks, and most of that is them arranging travel rather than us.

Speed is a benefit or a warning sign depending on the clinic. It should never be faster than the records review takes. A clinic willing to treat you without looking at your imaging is a red flag, not a convenience.

Where the US and Europe are genuinely better

Three things, said plainly.

1. Continuity of care. Your own doctor knows your history and can follow you for years. We can’t replicate that from Bangkok, and we don’t pretend to.
2. Legal recourse. If something goes wrong at home, you have a functioning system to pursue it in. Cross-border disputes are harder, and any honest clinic will tell you so.
3. Evidence depth. Where an approved therapy exists, the approved therapy has more data behind it. Novelty isn’t superiority.

If you have an approved, effective option at home, take it. The case for travel only starts when you don’t.

Where Thailand is genuinely better

• Cost, especially for multi-session protocols where travel gets amortised across more treatment
• Availability of protocols that can’t legally be offered in your home market
• Wait time, from assessment to treatment
• Concierge coordination — Thai medical tourism is organised around international patients in a way most Western clinics simply aren’t
• Time. A two-week treatment window in Bangkok is achievable. The same protocol at home can mean multiple trips to a specialist across months.

How to decide

Four questions, in this order:

1. Is there an approved, effective treatment for my condition where I live? If yes, pursue that first.
2. What does the total cost comparison look like once travel, accommodation and time off work are included? Not the procedure price. The total.
3. Is the protocol I’m considering available at home at all? If it isn’t, this is a comparison about availability, not price.
4. Can I verify the Thai clinic to my own satisfaction? Credentials, cell counts, imaging guidance, follow-up. If you can’t verify it, don’t travel for it.

Work through those four and travel still makes sense? Send us your records and we’ll tell you honestly whether we think we can help.

Our rule of thumb after ten years: we’d rather talk you out of an unnecessary trip than sell you one. The patients who do best here are the ones who arrived with clear expectations and a specific reason to be in Bangkok rather than at home.